Close Menu

Huntington's disease

Neurology biomarker firm C2N Diagnostics is accelerating its test development efforts with the aim of commercializing protein markers for the early detection of Alzheimer's as well as for use as primary endpoints in Phase III clinical trials of therapies for the disease.

Dutch gene therapy firm UniQure and academic collaborators have been awarded a three-year grant worth €2.5 million ($3.2 million) from the European Commission to develop a treatment for Huntington’s disease that combines RNAi and gene replacement.

Isis Pharmaceuticals this week announced that it has formed an alliance with Roche to develop antisense-based treatments for Huntington’s disease.

KineMed has entered into a collaboration with Isis Pharmaceuticals and CHDI Foundation that will use KineMed's biomarker platform in support of Isis' antisense therapeutics program for Huntington's disease.

Diagnostic biomarker firm KineMed said this week that it has signed a deal to provide its translational biomarker platform to Isis Pharmaceuticals and CHDI Foundation for use in their partnership developing an antisense-based treatment for Huntington's disease.

Utah's ARUP Laboratories has replaced its previous approach to PCR-based Huntington's disease testing with a triple repeat primed PCR method developed by ARUP's' Elaine Lyon.

Dutch gene therapy firm UniQure threw its hat into the RNAi ring this week, announcing that it has picked up non-exclusive access to Benitec Biopharma's proprietary expressed RNAi technology for use with its nascent Huntington's disease program.

NEW YORK (GenomeWeb News) – A genome-wide RNAi screen has turned up hundreds of potential drug targets for Huntington's disease, according to a paper published yesterday in PLoS Genetics.

NEW YORK (GenomeWeb News) – Horizon Discovery said today it has entered into a research collaboration covering gene editing with the Institute of Neurology, University College London.

Researchers from the University of Texas Southwestern Medical Center this month published new data describing the mechanism by which mismatch-containing double-stranded RNAs preferentially inhibit the mutant gene that causes Huntington's disease over the wild-type gene.

Pages

A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.

According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.

In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.